The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes

Bibliographic Details
Main Authors:	Reder, A, Ebers, G, Goodin, D, Li, D, Traboulsee, A, Beckman, K, Konieczny, A
Format:	Conference item
Published:	2008

Similar Items

The final results of the interferon beta-1b 16-year long-term follow-up study
by: Ebers, G, et al.
Published: (2006)

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
by: Ebers, G, et al.
Published: (2009)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
by: Reder, A, et al.
Published: (2010)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
by: Goodin, D, et al.
Published: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
by: Goodin, D, et al.
Published: (2012)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
by: Langdon, D, et al.
Published: (2007)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
by: Ebers, G, et al.
Published: (2005)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
by: Goodin, D, et al.
Published: (2012)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
by: Ebers, G, et al.
Published: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
by: Petkau, A, et al.
Published: (2004)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
by: Ebers, G, et al.
Published: (2010)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
by: Sibley, W, et al.
Published: (1994)

Treatment of multiple sclerosis with interferon beta-1b - Reply
by: Sibley, W, et al.
Published: (1997)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
by: Petkau, A, et al.
Published: (2004)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
by: Ebers, G, et al.
Published: (2011)

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
by: Duquette, P, et al.
Published: (1996)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
by: Goodin, D, et al.
Published: (2012)

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
by: Francis, G, et al.
Published: (2001)

Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003)

Experiences with interferon-beta-1b treatment in MS after three year follow-up
by: T Járdánházy, et al.
Published: (2002-05-01)

Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon
by: Sandro da Costa Ferreira, et al.

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
by: Sørensen, P, et al.
Published: (2010)

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
by: Lampasona, V, et al.
Published: (2003)

Cause of death in MS: Longterm follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study (BMJ Open (2012) 2 (e001972))
by: Goodin, D, et al.
Published: (2013)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
by: Cefaro Luca, et al.
Published: (2009-10-01)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
by: Palace, J, et al.
Published: (2010)

Test system for the detection of binding antibodies to interferon beta-1a for clinical use
by: E. A. Kuzminova, et al.
Published: (2018-02-01)

Resistance of Field-Isolated Porcine Epidemic Diarrhea Virus to Interferon and Neutralizing Antibody
by: Jung-Eun Park, et al.
Published: (2022-12-01)

Molecular mechanism of antibody neutralization of coxsackievirus A16
by: Chao Zhang, et al.
Published: (2022-12-01)

The significance of interferon-inducible protein-16 and anti-interferon-inducible protein-16 antibodies in rheumatoid arthritis: Relation to pulmonary disease and serological markers
by: Taghreed F M. Mostafa, et al.
Published: (2021-01-01)

Interferon beta treatment of multiple sclerosis.
by: Markovitz, D
Published: (1994)

S106: LONG-TERM FOLLOW-UP OF BETA-THALASSEMIA PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY
by: S Marktel, et al.
Published: (2022-01-01)

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
by: Rice, G, et al.
Published: (1999)

Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
by: Aric A. Prather, et al.
Published: (2023-05-01)

Endocrine Disorders in Adult Beta-Thalassemia Patients: Insights from a Long-Term Follow-Up
by: Seda Hanife Oğuz, et al.
Published: (2023-10-01)

Long-term follow up of EUVAS studies
by: Flossmann, O, et al.
Published: (2007)

Continued evasion of neutralizing antibody response by Omicron XBB.1.16
by: Julia N. Faraone, et al.
Published: (2023-10-01)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
by: Mark S. Freedman, et al.
Published: (2024-01-01)

Long term Follow up Study of Phone Contacts in Catalonia
by: D. Palao Vidal, et al.
Published: (2022-06-01)

Thrombotic microangiopathy associated with use of interferon-beta
by: Robles A, et al.
Published: (2012-06-01)